nivolumab
EMA Accepts Application for Subcutaneous Opdivo Across Multiple Indications
The application was based on results from a Phase III trial showing subcutaneous Opdivo was noninferior to intravenous use.
Tumor Forecasting Using Mechanistic Rules of Biology May Improve Predictive Models, Study Suggests
Premium
Incorporating mathematical biological rules into spatial models of tumor response can yield insights into tumor progression and response, early study shows.
First Patient Completes Dosing With Evaxion Biotech's Cancer Vaccine in Phase II Melanoma Trial
Patients with metastatic or unresectable melanoma are receiving 10 doses of the vaccine over 78 weeks with Merck's checkpoint inhibitor Keytruda.
Natera, Alliance for Clinical Trials in Oncology Partner for Urothelial Cancer Study
The study will assess the use of Natera's Signatera assay in guiding treatment among people with muscle-invasive urothelial cancer after bladder removal.
UK, Australian Researchers ID Tumor-Agnostic Microbiome Signature to Predict Opdivo-Yervoy Response
Premium
Researchers uncovered 22 bacteria that could predict which patients do and do not respond to combination checkpoint inhibitors across diverse cancer types.
Apr 27, 2023
Feb 2, 2023
Nov 17, 2022